首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Efficacy of aspergillomarasmine A/meropenem combinations with and without avibactam against bacterial strains producing multiple β-lactamases
【2h】

Efficacy of aspergillomarasmine A/meropenem combinations with and without avibactam against bacterial strains producing multiple β-lactamases

机译:曲霉马拉辛 A/美罗培南联合用和不用阿维巴坦对产生多种 β-内酰胺酶的细菌菌株的疗效

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The effectiveness of β-lactam antibiotics is increasingly threatened by resistant bacteria that harbor hydrolytic β-lactamase enzymes. Depending on the class of β-lactamase present, β-lactam hydrolysis can occur through one of two general molecular mechanisms. Metallo-β-lactamases (MBLs) require active site Zn2+ ions, whereas serine-β-lactamases (SBLs) deploy a catalytic serine residue. The result in both cases is drug inactivation via the opening of the β-lactam warhead of the antibiotic. MBLs confer resistance to most β-lactams and are non-susceptible to SBL inhibitors, including recently approved diazabicyclooctanes, such as avibactam; consequently, these enzymes represent a growing threat to public health. Aspergillomarasmine A (AMA), a fungal natural product, can rescue the activity of the β-lactam antibiotic meropenem against MBL-expressing bacterial strains. However, the effectiveness of this β-lactam/β-lactamase inhibitor combination against bacteria producing multiple β-lactamases remains unknown. We systematically investigated the efficacy of AMA/meropenem combination therapy with and without avibactam against 10 Escherichia coli and 10 Klebsiella pneumoniae laboratory strains tandemly expressing single MBL and SBL enzymes. Cell-based assays demonstrated that laboratory strains producing NDM-1 and KPC-2 carbapenemases were resistant to the AMA/meropenem combination but became drug-susceptible upon adding avibactam. We also probed these combinations against 30 clinical isolates expressing multiple β-lactamases. E. coli, Enterobacter cloacae, and K. pneumoniae clinical isolates were more susceptible to AMA, avibactam, and meropenem than Pseudomonas aeruginosa and Acinetobacter baumannii isolates. Overall, the results demonstrate that a triple combination of AMA/avibactam/meropenem has potential for empirical treatment of infections caused by multiple β-lactamase-producing bacteria, especially Enterobacterales.
机译:β-内酰胺类抗生素的有效性越来越受到含有水解 β-内酰胺酶的耐药细菌的威胁。根据存在的 β-内酰胺酶的类别,β-内酰胺水解可以通过两种一般分子机制之一发生。金属β内酰胺酶 (MBL) 需要活性位点 Zn2+ 离子,而丝氨酸内酰胺酶 (SBL) β 内酰胺酶 (SBL) 部署催化丝氨酸残基。在这两种情况下,结果都是通过打开抗生素的 β-内酰胺弹头使药物失活。MBL 对大多数 β-内酰胺类药物具有耐药性,并且对 SBL 抑制剂不敏感,包括最近批准的二氮杂双环辛烷,例如阿维巴坦;因此,这些酶对公共卫生的威胁越来越大。Aspergillomarasmine A (AMA) 是一种真菌天然产物,可以挽救 β-内酰胺类抗生素美罗培南对表达 MBL 的细菌菌株的活性。然而,这种 β-内酰胺/β-内酰胺酶抑制剂组合对产生多种 β-内酰胺酶的细菌的有效性仍然未知。我们系统研究了 AMA/美罗培南联合治疗联合和不联合阿维巴坦对 10 种大肠杆菌和 10 种肺炎克雷伯菌实验室菌株串联表达单一 MBL 和 SBL 酶的疗效。基于细胞的测定表明,产生 NDM-1 和 KPC-2 碳青霉烯酶的实验室菌株对 AMA/美罗培南组合具有耐药性,但在添加阿维巴坦后变得对药物敏感。我们还针对表达多种 β-内酰胺酶的 30 种临床分离株探测了这些组合。大肠杆菌、阴沟肠杆菌和肺炎克雷伯菌临床分离株比铜绿假单胞菌和鲍曼不动杆菌分离株更易感染 AMA、阿维巴坦和美罗培南。总体而言,结果表明,AMA/avibactam/美罗培南的三联疗法有可能对由多种产生 β-内酰胺酶的细菌(尤其是肠杆菌属)引起的感染进行经验性治疗。

著录项

代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号